GLP‑1 receptor agonists
GLP 1 receptor agonists show neuroprotective effects in animal models of diabetes
... 2017). GLP-1 receptors are expressed in the brains of rodents, primates and humans (Merchenthaler et ...2016). GLP-1 receptor agonists such as exendin- 4 or liraglutide can ...
20
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
... [4]. GLP-1 receptor agonists stimulate glucose-medicated insulin secretion, suppress glucagon secretion, delay gas- tric emptying, and decrease appetite, thus explaining the considerable ...
9
Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists
... the GLP-1 receptor agonists outlined in Table 2, therapy may individual- ized to provide each patient with the best opportunity for successful ...
12
Extra Glycemic Impacts of GLP 1 Receptor Agonists: Benefits of a Class Effect?
... and GLP-1 has been demonstrated in experiments in rodents showing that subthreshold doses of leptin increased the ability of GLP-1 inhibit food ...more, GLP-1 receptor ...
15
Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence
... Among GLP-1 Receptor Agonists and DPP-4 Inhibitors There are numerous factors to consider when selecting among the treatment options for type 2 diabetes, including the five incretin-based ...
10
GLP 1 receptor agonists for Parkinson's disease (Protocol)
... that GLP-1 can cause weight loss (Vilsbøll 2012), it is known that the amount of levodopa and its maximum concentration in plasma are negatively correlated with body weight (Müller 2000), and consequently ...
14
Emerging role of GLP-1 receptor agonists in the treatment of obesity
... hormone, GLP-1, also plays an important role in glucose homeostasis. GLP-1 receptor agonists, such as exenatide and liraglutide, have been developed and are already approved for ...
11
<p>Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data</p>
... (GLP-1) receptor agonists have been available as glu- cose-lowering therapies for people with type 2 diabetes since 2006, when twice-daily exenatide was ...” GLP-1 ...
6
Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
... balanced GLP-1RA and DPP-4i initiators via pro- pensity score matching (PSM), using the nearest neigh- bor method and the logit distance, with maximum caliper set to ...
12
The GLP 1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK dependent mechanism
... Previous studies in rodent [14, 44] and human cell lines [16] have shown that GLP-1 and exendin-4 can stimulate glucose uptake. In L6 myotubes, exendin-4 augments insulin-stimulated glucose uptake via a ...
13
The effect of glucagon like peptide 1 (GLP 1) receptor agonists on cell viability, ADAM10 maturation and the proteolysis of ADAM10 substrates in SH SY5Y cells
... The combination of treatment with exendin-4 and TG showed a significant decline in the expression of NLGN-1 in comparison to TG alone (Fig. 3.3.6). Additionally, the combination of treatment with both the stressor ...
109
Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK
... Objective: To use a discrete choice experiment (DCE) to evaluate preferences for the actual treatment features and overall profiles of two injectable glucagon-like peptide-1 receptor agonists ...
12
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
... Differences also exist within drug classes. Exenatide and liraglutide have slightly better weight and efficacy out- comes compared to other GLP-1RA. Once-daily or weekly formulations may be preferred by patients ...
11
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
... of GLP-1 agonists have emerged recently, point- ing to a decrease of major adverse cardiovascular and cerebrovascular events (MACCE) including stroke, MI, cardiac mortality, acute coronary syndrome, ...
11
Role and development of GLP-1 receptor agonists in the management of diabetes
... Figure 1 Structures of native GLP-1, exenatide, and liraglutide. The N-terminal dipeptide “HA” (in green letters) of GLP-1 and liraglutide is the proteolytic cleavage site for DPP 4. ...
13
Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists
... if GLP-1RAs could affect sclerostin ...that GLP-1r is mainly expressed in immature osteoblasts, GLP-1r can be present in osteocytes where it co-localise with sclerostin [38], suggesting that ...
24
Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes
... weekly GLP-1 receptor agonists differ in terms of injection treatment process ...ments: 1) requirements for reconstitution (ie, mixing the medication) prior to injection, 2) waiting ...
9
Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies
... the GLP-1 receptor agonists and DPP-4 inhibitors in reducing PPG are discussed herein, with recent clinical trial results summarized in Tables ...
19
Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies
... and GLP-1 receptor agonists by estimating the daily usage and costs of treatment with exenatide twice daily and liraglutide in the real world ...of GLP-1 receptor agonist ...
9
Two novel dual GLP 1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease
... of GLP-1 and GIP have shown neuroprotective effects in animal models of Alzheimer’s disease (Bomfim et ...that GLP-1 receptor agonists also have neuroprotective effects in animal ...
28